AstraZeneca Pharma India Limited

NSEI:ASTRAZEN Stock Report

Market Cap: ₹158.4b

AstraZeneca Pharma India Valuation

Is ASTRAZEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ASTRAZEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ASTRAZEN (₹6319.85) is trading above our estimate of fair value (₹8.51)

Significantly Below Fair Value: ASTRAZEN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ASTRAZEN?

Key metric: As ASTRAZEN is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ASTRAZEN. This is calculated by dividing ASTRAZEN's market cap by their current revenue.
What is ASTRAZEN's PS Ratio?
PS Ratio10.7x
Sales₹14.85b
Market Cap₹158.42b

Price to Sales Ratio vs Peers

How does ASTRAZEN's PS Ratio compare to its peers?

The above table shows the PS ratio for ASTRAZEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.5x
ERIS Eris Lifesciences
7.5x16.2%₹187.0b
524558 Neuland Laboratories
12.5x23.3%₹191.2b
MARKSANS Marksans Pharma
5.9x16.2%₹139.9b
524742 Caplin Point Laboratories
8.1x13.2%₹149.4b
ASTRAZEN AstraZeneca Pharma India
10.7xn/a₹158.4b

Price-To-Sales vs Peers: ASTRAZEN is expensive based on its Price-To-Sales Ratio (10.7x) compared to the peer average (8.5x).

Price to Sales Ratio vs Industry

How does ASTRAZEN's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
NECLIFE Nectar Lifesciences
0.4xn/aUS$89.20m
539561 Remedium Lifecare
0.07xn/aUS$28.41m
532637 Mangalam Drugs & Organics
0.5xn/aUS$20.04m
524412 Aarey Drugs & Pharmaceuticals
0.3xn/aUS$19.22m
ASTRAZEN 10.7xIndustry Avg. 3.1xNo. of Companies20PS02.44.87.29.612+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ASTRAZEN is expensive based on its Price-To-Sales Ratio (10.7x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is ASTRAZEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ASTRAZEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ASTRAZEN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

7D

-8.8%

1Y

33.1%